10:55 AM EDT, 08/02/2024 (MT Newswires) -- Inspire Medical Systems ( INSP ) said Friday that the US Food and Drug Administration approved its Inspire V therapy system.

The system includes the next generation neurostimulator along with Bluetooth patient remote and physician programmer, according to the company.

The company said it is targeting a soft launch of the Inspire V therapy system in late 2024 followed by a full launch in 2025.

Shares of Inspire Medical ( INSP ) were up 3.5% in recent trading.

Price: 150.15, Change: +5.04, Percent Change: +3.47